cyclin gene family members. TNP-470 may also inhibit cdc2 and cdk2 kinase activation in endothelial cells (Kato et al, 1994) . Alteration of thrombospondin production, an important regulator of endothelial cell proliferation and angiogenesis, is another proposed mechanism of action (Abe et al, 1994; Kato et al, 1994) .
Kusaka and associates demonstrated inhibition of in vitro capillary growth and induction of avascular zones in the chick chorioallantoic membrane assay (Kusaka et al, 1991) . A rat corneal micropocket assay showed 20 µg TNP-470 per cornea suppressed the number and length of blood vessels induced by basic fibroblast growth factor (bFGF). In the sponge implantation model in rats, systemic administration of TNP-470 inhibited angiogenesis induced by bFGF. Finally, in the rat blood vessel organ culture assay, 1 ng ml -1 TNP-470 inhibited capillary-like tube formation (Kusaka et al, 1991; Bauer et al, 1998) . TNP-470 also inhibited solid tumour growth in animal models (Ingber et al, 1990; Kusaka et al, 1991; Kato et al, 1994; O'Reilly et al, 1995) . Ingber and colleagues reported that 30 mg kg -1 TNP-470 every other day inhibited the growth of Lewis lung carcinoma, B16 melanoma, and other mouse tumours (Ingber et al, 1990) . In some studies, tumour inhibition was noted with administration as infrequently as once a week. The doselimiting toxicity of TNP-470 in dogs was cerebral bleeding when high doses were given as a bolus (Masiero et al, 1997) .
Logothetis et al have completed a phase I study of TNP-470 in patients with AIPC (Logothetis et al, 1997) . They reported a maximum tolerated dose of 70.88 mg m -2 when a 1 h intravenous infusion was administered every other day for 28 days, repeated every 6 weeks. In this trial, several patients had serum PSA elevations while receiving active therapy that reversed upon discontinuation. Sartor reported a TNP-470 withdrawal phenomenon in a single patient with metastatic prostate cancer (Sartor, 1995) . Based on these observations, we wanted to determine if TNP-470, or its metabolite, AGM-1883, alters PSA secretion in an in vitro system. Furthermore, we wanted to determine if protein expression or transcription was altered in LNCaP cells exposed to clinically achievable concentrations of either of these compounds. 
MATERIALS AND METHODS

Cell culture
The human androgen-dependent prostate carcinoma cell line, LNCaP, was obtained from the American Type Culture Collection (Manassas, VA, USA) and grown as directed. Cells, passage 25, were plated at 30 000 cells per 2-cm well. TNP-470 and AGM-1883 were gifts from the Takeda Pharmaceutical Ltd (Oseka, Japan) and prepared as stock solutions in dimethyl sulfoxide (DMSO). Serial dilutions were prepared in culture medium to produce final concentrations of 50, 500 and 1000 ng ml -1 . The final DMSO concentration was 0.5%. Cells were treated daily.
PSA quantification
Every 24 h, the supernatants were collected. Adherent cells were trypsinized and counted on a Coulter Z1 counter (Coulter Electronics, Hialeah, FL, USA). PSA secreted into the supernatant was measured using the Tandem-E PSA assay (Hybritech, San Diego, CA, USA) according to the company's instructions. The amount of PSA secreted per cell was calculated for every 24 h period.
Immunoblots for PSA and AR
Following treatment for 120 h, adherent cells were collected by trypsinization. The cells were washed with phosphate-buffered saline and pelleted. Cytosolic protein was extracted by resuspending cells in 10 mM HEPES, pH 7.4, 1 mM EDTA and protease inhibitors (complete Ø , Boehringer-Mannheim, Indianapolis, IN, USA) followed by three cycles of freezing and thawing. Cellular debris was pelleted and the supernatant saved. The amount of protein was determined using the BioRad protein assay (BioRad, Hercules, CA, USA). Equal amounts of protein were separated on polyacrylamide-SDS gels, then transferred to nitrocellulose. Blots were developed according to Western-Light chemiluminescent detection system (Tropix, Bedford, MA, USA) using a mouse anti-PSA (Cappel, Aurora, OH, USA) or a mouse anti-human androgen receptor (AR) antibody (Pharmingen, San Diego, CA, USA). The secondary antibody was alkaline phosphatase-conjugated goat anti-mouse IgG (Promega, Madison, WI, USA).
Reverse transcriptase-polymerase chain reaction assay
LNCaP cells, passage 26, were plated at a density of 45 000 cells per 2-cm well. After 48 h, the cells were treated with 50 ng ml -1 TNP-470. At each time-point, the supernatant was aspirated and the adherent cells lysed in TriZol (Life Technologies, Gaithersburg, MD, USA). Total RNA was extracted according to the manufacturer's protocol. Contaminating genomic DNA was digested with DNAse I (Ambion, Austin, TX, USA) and first strand cDNA was prepared using an oligo(dT) primer and Superscript TM II reverse transcriptase (Life Technologies, Gaithersburg, MD, USA). Each cDNA:RNA hybrid was digested with RNase H. The final cDNA product was diluted threefold in 10 mM Tris-HCl, pH 7.4, 1 mM EDTA. PSA and AR primers were synthesized by BioServe Biotechnologies (Laurel, MD, USA) and are as follows: PSA 614, 5′-ATGAGCCTCCTGAAGAATCGATTCCTC-3′; PSA 1154, 5′-AGTCTTGGCCTGGTCATTTCCAAGGT-3′; AR 2381, 5′-TGGGGCTCATGGTGTTTG-3′; and AR 2881, 5′-CAGAAAG-GATCTTGGGCAC-3′. Primers are numbered to correspond to the base in the published sequence to where the primers anneal. HMR GAPDH polymerase chain reaction (PCR) primers were purchased from Clontech (Palo Alto, CA, USA). For each pair of primers, the sequence to be amplified was subcloned into pCR-Script™ AMP SK(+) (Stratagene, San Diego, CA, USA) to serve as a positive control. PCR was performed on 2 ng of positive control or 1 µl diluted cDNA in the presence of 50 mM Tris-HCl, pH 8.3, 250 µg ml -1 bovine serum albumin, 2 mM magnesium chloride for AR or 3 mM magnesium chloride for PSA and GAPDH, 0.5% Ficoll 400, 1 mM tartrazine, 500 µM of each dNTP, 1 µM of each primer, and 0.5 U AmpliTaq (Perkin-Elmer, Foster City, CA, USA) in a volume of 10 µl. Thermal cycling parameters for each primer set were optimized fall within a linear amplification range. The thermal cycling programme consisted of denaturation at 94°C for 15 s followed by several cycles of denaturation at 94°C for 0 s, annealing at the optimized temperature for 0 s, and extension at 72°C for 30 s. The cycle number and annealing temperature for the three primer sets were: 27 cycles and 60°C for PSA; 29 cycles and 55°C for AR; and 22 cycles and 50°C for GAPDH. PCR products (7 µl) were separated on agarose gels. The gels were stained with SYBR Green I (Molecular Probes, Eugene, OR, USA) and scanned on a Fluorimager SI (Molecular Dynamics, Sunnyvale, CA, USA). Bands were quantitated using NIH Image 1.6. Differences in RNA isolation and cDNA synthesis efficiencies between time-points and duplicates were accounted for by normalization of each band to the level of GAPDH detected at the same time-point. Induction was determined relative to the initial time-point.
RESULTS
After 120 h, TNP-470 treatment resulted in a 40.6% decrease in cell number at the highest concentration ( Figure 1A) . The mean number of cells per well was 3.82 × 10 4 at 50 ng ml, 4.47 × 10 4 at 500 ng ml -1 , and 4.65 × 10 4 at 1000 ng ml -1 TNP-470. The mean cell number in control wells was 7.83 × 10 4 . AGM-1883 had a minimal effect on cell viability resulting in a 16.6% decrease in cell number at the highest concentration ( Figure 1B) . After 120 h, there were 3.84 × 10 4 , 4.74 × 10 4 , and 3.47 × 10 4 cells/well at 50, 500, and 1000 ng ml -1 , respectively, compared to 4.16 × 10 4 cells/well for controls.
TNP-470 treatment resulted in a 1.1-to 1.5-fold induction in PSA secretion per cell that was concentration-dependent ( Figure  2A ). Lower concentrations of TNP-470 up-regulated PSA secretion per cell better than higher concentrations. The concentration of PSA in the supernatant at 120 h was 2616.5 fg/cell at 50 ng ml -1 , 2055.9 fg/cell at 500 ng ml -1 , 1921.5 fg/cell at 1000 ng ml -1 versus 1716.6 fg/cell for the controls. The same trends were observed for AGM-1883 with the amount of PSA secreted per cell up-regulated approximately 30-70% compared to controls ( Figure  2B ). However, no concentration-dependency was observed in response to AGM-1883. Immunoblots of cell extracts treated with TNP-470 or AGM-1883 for 120 h showed equivalent increases in intracellular PSA (Figure 3) . The AR, on the other hand, shows a slight down-regulation in intracellular protein levels relative to control (approximately 10% decrease). This decrease may be due to instability of the AR protein in the presence of these agents. The effect of TNP-470 on PSA and AR transcription was quantitated using RT-PCR. Both PSA and AR showed a transcriptional up-regulation that peaked within 30 min of TNP-470 exposure then declined to baseline levels by 9 h (Figure 4) . PSA transcription was increased 1.4-fold at 30 min, while AR transcription was induced 1.2-fold. The increased transcriptional activity from the PSA gene accounts for the increased amount of PSA secreted per cell. Increased AR transcription was reflected by similar increases at the protein level.
DISCUSSION
TNP-470, a semi-synthetic derivative of fumagillin, was discovered by Ingber et al (1990) to inhibit capillary endothelial cell growth. Figg et al (1994 Figg et al ( , 1997b characterized the pharmacokinetic profile of TNP-470 obtained as part of a dose escalation phase I trial. There was a linear relationship between TNP-470 dose and AUC (inf) and between TNP-470 dose and peak plasma concentrations (C max ). The C max ranged from 6.6 ng ml -1 at the lowest dose level to 597.1 ng ml -1 at the highest dose level. TNP-470 was rapidly cleared from the circulation with a short terminal half-life (0.88 ± 2.5 h) consistent with preclinical data. The Cmax of AGM-1883, an active metabolite, ranged between 0.4 to 158.1 ng ml -1 . Concentrations of TNP-470 that yielded in vitro activity were clinically achievable. In our in vitro experiments, TNP-470 causes an initial decrease in LNCaP cell number at 48 h. Subsequently, cell number was constant throughout the remainder of the treatment period. Cytotoxicity was not noted. AGM-1883 also showed an initial decrease in cell number compared to the control. However, the cell number continued to increase throughout the treatment period, but with a slower doubling time than untreated cells. Thus, it appears that TNP-470 has a slightly stronger cytostatic activity than its metabolite. Logothetis et al (1997) reported the maximum tolerated dose of TNP-470 to be 70.8 mg m -2 and the dose-limiting toxicity as a reversible neuropsychiatric symptom complex (asthenia, ataxia, agitation). They were unable to document any anti-tumour activity in their phase I study, but did note a transient stimulation of serum PSA in a subset of patients. In fact, between 33% and 100% of patients at each dose level had > 50% decline in PSA on two consecutive measurements after cessation of therapy. A case report of a single patient treated with TNP-470 illustrates the dilemma of alterations in PSA independent of anti-tumoral activity may result (Logothetis et al, 1997) . In this instance, the patient had a rise in his serum PSA concentration while receiving therapy, followed by a decline in PSA with the discontinuation of TNP-470 ( Figure 5 ). The apparent dissociation between PSA levels and tumour progression in this case and the experience reported by the MD Anderson Cancer Center (unpublished) suggests that this phenomena of PSA expression is reflected clinically.
Our data show that TNP-470 results in a moderate to substantial increase in PSA secreted per cell that is concentration-dependent. Equivalent increases in intracellular PSA were also detected. The active metabolite, AGM-1883, also increased PSA production. However, the increase in PSA secretion in response to AGM-1883 treatment was not concentration-dependent. The increased transcription activity from the PSA gene accounts for the increased amount of PSA produced and secreted by the cell. Increased AR protein could also be accounted for by corresponding increases in AR transcription. Thus, it appears that the mechanism of PSA upregulation by TNP-470 is at the transcriptional level. For individuals with prostate cancer receiving TNP-470, these data suggest that PSA is not a reliable surrogate marker.
